What to Expect From Becton, Dickinson and Company’s Next Quarterly Earnings Report

Based in Franklin Lakes, New Jersey, Becton, Dickinson and Company (BDX) is a leader in medical technology. It is renowned for its extensive portfolio of medical devices, laboratory equipment, and diagnostic products, including syringes, needles, and specimen collection systems. With a market cap of $66.97 billion, BDX is recognized for its innovation, customer-centric approach, and commitment to improving healthcare outcomes. BDX is scheduled to announce its fiscal Q3 earnings before the market opens on Thursday, Aug. 1.

Ahead of the event, analysts expect BDX to report a profit of $3.31 per share, up 11.8% from $2.96 in the year-ago quarter. The company has consistently surpassed or matched Wall Street’s EPS estimates in its last four quarterly reports. Its adjusted earnings of $3.17 per share for the last quarter surpassed the consensus estimate by 7.1%.